Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance

Current Opinion in Investigational Drugs

Volumn 5, Issue 10, 2004, Pages 1045-1050

  Patsouris, David ^a   Müller, Michael ^a   Kersten, Sander ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Fibrates; Glucose disposal; Hepatic glucose production; Insulin resistance; PPARs; Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL; DRUG POTENTIATION; HUMAN; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIGANDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 16644381634     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Bouche C, Serdy S, Kahn CR, Goldfine AB: The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev (2004): doi:10.1210/er.2003-0026.
2. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature (2000) 405(6785):421-424.
3. Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med (2004) 10(4):355-361.
4. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev (1999) 20(5):649- 688.
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem (1995) 270(22):12953-12956.
6. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B: Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology (2001) 142(10):4195-4202.
7. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology (1996) 137(1):354-366.
8. Rosen ED, Spiegelman BM: Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol (2000) 16:145-171.
9. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM et al: Regulation of fasted blood glucose by resistin. Science (2004) 303(5661):1195- 1198.
10. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K et al : Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 8(11):1288-1295.
11. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W: Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem (2000) 275(37):28488-28493.
12. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Wllson TM, Kliewer SA: Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology (2001) 142(3):1269-1277.
13. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD: Splanchnic lipolysis in human obesity. J Clin Invest (2004) 113(11):1582- 1588.
14. Chen X, Iqbal N, Boden G: The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest (1999) 103(3):365-372.
15. Rebrin K, Steil GM, Mittelman SD, Bergman RN: Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest (1996) 98(3):741-749.
16. Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, Koenig W, März W, Tafuri S, Wahli W, Müller M et al: PPARα governs glycerol metabolism. J Clin Invest (2004) 114(1):94-103.
17. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA: A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med (2002) 8(10):1122-1128.
18. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wlkes J, Evans RM, Olefsky J: Muscle-specific Pparg deletion causes insulin resistance. Nat Med (2003) 9(12):1491-1497.
19. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM et al: Muscle-specific PPARy-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 112(4):608-618.
20. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, Auwerx J: Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARy hypomorphic mice. Proc Natl Acad Sci USA (2003) 100(24): 14457-14462.
21. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM: Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA (2003) 100(26):15712-15717.
22. Imai T, Takakuwa R, Marchand S, Dentz E, Bornert JM, Messaddeq N, Wendling O, Mark M, Desvergne B, Wahli W, Chambon P, Metzger D: Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA (2004) 101(13):4543-4547.
23. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, Xiao Y, Floyd D, Liang J, Li E, Song Q, Chen YE: Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA (2004) 101(29):10703-10708.
24. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA: Troglitazone action is independent of adipose tissue. J Clin Invest (1997) 100(11):2900-2908.
25. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML: Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest (2000) 106(10):1221-1228.
26. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK: Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression. J Biol Chem (2003) 278(1):498-505.
27. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML: Liver peroxisome proliferator- activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 278(36):34268-34276.
28. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, Gonzalez FJ: Liver-specific disruption of PPARy in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 111(5):737-747.
29. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti JR Jr: A selective peroxisome proliferator-activated receptor-γ (PPARγ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol (2000) 14(9):1425-1433.
30. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM et al: A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell (2001) 8(4):737-747.
31. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest (1999) 103(11):1489-1498.
32. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, Semenkovich CF: PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest (2001) 107(8):1025-1034.
33. Bandsma RH, Van Dijk TH, Harmsel At A, Kok T, Reijngoud DJ, Staels B, Kuipers F: Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor α-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast. J Biol Chem (2004) 279(10):8930-8937.
34. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B: PPAR-α-null mice are protected from high-fat diet-induced insulin resistance. Diabetes (2001) 50(12):2809-2814.
35. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M: PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3. Nat Med (2004) 10(5):530-534.
36. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D: Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes (2003) 52(7):1770-1778.
37. Rizvi F, Puri A, Bhatia G, Khanna AK, Wulff EM, Rastogi AK, Chander R: Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model. Biochem Biophys Res Commun (2003) 305(2):215-222.
38. Larsen PJ, Jensen PB, Sorensen RV, Larsen LK, Vrang N, Wulff EM, Wassermann K: Differential influences of peroxisome proliferator-activated receptors-γ and -α on food intake and energy homeostasis. Diabetes (2003) 52(9):2249-2259.
39. Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH, Lee KU: Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: Comparison with PPAR-γ activation. Diabetes (2003) 52(9):2331-2337.
40. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem (2000) 275(22):16638-16642.
41. Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, Witters LA, Unger RH: PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci USA (2002) 99(18):11848-11853.
42. Rieusset J, Roques M, Bouzakri K, Chevillotte E, Vidal H: Regulation of p85α phosphatidylinositol-3-kinase expression by peroxisome proliferator-activated receptors (PPARs) in human muscle cells. FEBS Lett (2001) 502(3):98-102.
43. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, Reitman ML: WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem (2002) 277(27):24484-24489.
44. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-γ activation. Diabetes (2001) 50(2):411-417.
45. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL, Kraus WE: Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPAR δ. J Biol Chem (2002) 277(29):26089-26097.
46. Hamadeh HK, Bushel PR, Jayadev S, Martin K, DiSorbo O, Sieber S, Bennett L, Tennant R, Stoll R, Barrett JC, Blanchard K et al: Gene expression analysis reveals chemical-specific profiles. Toxicol Sci (2002) 67(2):219-231.
47. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell (2003) 113(2):159-170.
48. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA: Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J (2003) 17(15):2299-2301.